Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 6/20 | 0.38 |
| ▸ | MMP13 | P45452 | 4/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7745789 | 0.87 | TSHR (0.47) | ALDH1A1CYP1A2 | |
| SCHEMBL5053068 | 0.81 | CFTR (0.42) | ALDH1A1CYP1A2 | |
| SCHEMBL5060074 | 0.77 | MMP1 (0.45) | MMP1MMP13 | |
| SCHEMBL5053079 | 0.76 | SLC1A2 (0.46) | — | |
| SCHEMBL5051100 | 0.74 | SLC1A2 (0.39) | — | |
| SCHEMBL7358486 | 0.73 | CYP1A2 (0.43) | ALDH1A1CYP1A2 | |
| SCHEMBL7607501 | 0.73 | MEN1 (0.57) | ALDH1A1MMP1MMP13 | |
| SCHEMBL7398125 | 0.72 | GRM2 (0.48) | ALDH1A1CYP1A2 | |
| SCHEMBL5053034 | 0.72 | CYP2C9 (0.37) | — | |
| SCHEMBL7402157 | 0.71 | CYP1A2 (0.46) | ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6313159-B1 | FOR THERAPY OF GLUTAMATE MEDIATED DISEASE, DISORDER SUCH AS: STROKE, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE, SCHIZOPHRENIA, ISCHEMIA, PAIN, DIABETIC NEUROPATHY, TRAUMA, NERVOUS INSULT | GUILFORD PHARMACEUTICALS INC. | 2001-11-06 | — | — | US | claimed |
| WO-2001014390-A2 | METABOTROPIC GLUTAMATE RECEPTOR LIGAND DERIVATIVES AS NAALADase INHIBITORS | GUILFORD PHARMACEUTICALS (US) | 2001-03-01 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-6313159-B1 | FOR THERAPY OF GLUTAMATE MEDIATED DISEASE, DISORDER SUCH AS: STROKE, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE, SCHIZOPHRENIA, ISCHEMIA, PAIN, DIABETIC NEUROPATHY, TRAUMA, NERVOUS INSULT | GUILFORD PHARMACEUTICALS INC. | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | ALDH1A1 257/4885CYP1A2 4283/4885MMP1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.